Skip to main content
SpringerLink
Log in

Anticoagulation in Splanchnic Vein Thrombosis With and Without Underlying Liver Disease

  • Conference paper
  • First Online:
Portal Hypertension VII

Abstract

Vascular disorders of the liver are a heterogenous group of diseases that, albeit affecting less than 5/10,000 patients, collectively represent an important health issue in the field of liver diseases. The common characteristic of these disorders is that they cause non-cirrhotic portal hypertension, which may be associated with significant morbidity and mortality. Among vascular liver diseases, there are splanchnic vein thrombosis, particularly portal vein thrombosis, and hepatic vein thrombosis (i.e., Budd–Chiari syndrome). The occurrence of thrombosis in the liver venous vessels is determined by an alteration in the physiological equilibrium that regulates the balance between coagulation and anticoagulation. As hypercoagulability plays a major role in the pathophysiology of thrombosis in these vessels, anticoagulation is a cornerstone in the treatment of these patients, including those with cirrhosis. This chapter reviews the current knowledge and future directions regarding anticoagulation for the treatment of splanchnic and hepatic veins thrombosis in patients with and without underlying liver disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zanetto A, Pellone M, Senzolo M. Milestones in the discovery of Budd-Chiari syndrome. Liver Int. 2019;39:1180–5.

    Article  PubMed  Google Scholar 

  2. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut. 1997;40:798–800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031–8.

    Article  CAS  PubMed  Google Scholar 

  4. McCarthy PM, van Heerden JA, Adson MA, Schafer LW, Wiesner RH. The Budd-Chiari syndrome. Medical and surgical management of 30 patients. Arch Surg. 1985;120:657–62.

    Article  CAS  PubMed  Google Scholar 

  5. Wang ZG, Jones RS. Budd-Chiari syndrome. Curr Probl Surg. 1996;33:83–211.

    Article  CAS  PubMed  Google Scholar 

  6. Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger MH, Condat B, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology. 2006;44:1308–16.

    Article  PubMed  Google Scholar 

  7. Seijo S, Plessier A, Hoekstra J, Dell’era A, Mandair D, Rifai K, Trebicka J, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–8.

    Article  PubMed  Google Scholar 

  8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.

    Article  Google Scholar 

  9. Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, Benhamou JP. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology. 1994;106:1042–7.

    Article  CAS  PubMed  Google Scholar 

  10. Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, Boudet MJ, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84–9.

    Article  CAS  PubMed  Google Scholar 

  11. Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L. High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. J Thromb Thrombolysis. 2018;45:106–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost. 1993;70:736–42.

    Article  CAS  PubMed  Google Scholar 

  13. Randi ML, Tezza F, Scapin M, Duner E, Scarparo P, Scandellari R, Fabris F. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol. 2010;123:140–5.

    Article  CAS  PubMed  Google Scholar 

  14. De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, Randi ML, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6:e493.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Chagneau C, Roy L, Guilhot J, Gloria O, Ollivier-Hourmand I, Bureau C. Impact o cytoreductive therapy on the outcome of patients with myeloproliferative neoplasms and hepatosplanchnic vein thrombosis. J Hepatol. 2013;58:857A.

    Google Scholar 

  16. Desbois AC, Rautou PE, Biard L, Belmatoug N, Wechsler B, Resche-Rigon M, Zarrouk V, et al. Behcet’s disease in Budd-Chiari syndrome. Orphanet J Rare Dis. 2014;9:104.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Alvarez-Larran A, Pereira A, Magaz M, Hernandez-Boluda JC, Garrote M, Cuevas B, Ferrer-Marin F, et al. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. Ann Hematol. 2020;99:791–8.

    Article  CAS  PubMed  Google Scholar 

  18. Dogrul AB, Yankol Y, Mecit N, Kanmaz T, Acarli K, Kalayoglu M. Orthotopic liver transplant for Budd-Chiari syndrome: an analysis of 14 cases. Exp Clin Transplant. 2016;14:641–5.

    PubMed  Google Scholar 

  19. Mentha G, Giostra E, Majno PE, Bechstein WO, Neuhaus P, O’Grady J, Praseedom RK, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol. 2006;44:520–8.

    Article  PubMed  Google Scholar 

  20. Potthoff A, Attia D, Pischke S, Mederacke I, Beutel G, Rifai K, Deterding K, et al. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. Liver Int. 2015;35:2042–9.

    Article  PubMed  Google Scholar 

  21. Westbrook RH, Lea NC, Mohamedali AM, Smith AE, Orr DW, Roberts LN, Heaton ND, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18:819–27.

    Article  PubMed  Google Scholar 

  22. Chinnakotla S, Klintmalm GB, Kim P, Tomiyama K, Klintmalm E, Davis GL, Trotter JF, et al. Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation. 2011;92:341–5.

    Article  CAS  PubMed  Google Scholar 

  23. Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, Klintmalm GB, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation. 2002;74:1090–5.

    Article  CAS  PubMed  Google Scholar 

  24. Rautou PE, Douarin L, Denninger MH, Escolano S, Lebrec D, Moreau R, Vidaud M, et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol. 2011;54:56–63.

    Article  PubMed  Google Scholar 

  25. Husova L. Use of idarucizumab in clinical practice: a case report. Vnitr Lek. 2019;65:377–8.

    Article  PubMed  Google Scholar 

  26. Sharma S, Kumar R, Rout G, Gamanagatti SR, Shalimar. Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention. J Gastroenterol Hepatol. 2020;35(4):654–62.

    Article  CAS  PubMed  Google Scholar 

  27. Singal AK, Kamath PS, Tefferi A. Mesenteric venous thrombosis. Mayo Clin Proc. 2013;88:285–94.

    Article  PubMed  Google Scholar 

  28. Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:210–8.

    Article  PubMed  Google Scholar 

  29. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683–8.

    Article  CAS  PubMed  Google Scholar 

  30. Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol. 2005;16:651–61.

    Article  PubMed  Google Scholar 

  31. Benmassaoud A, AlRubaiy L, Yu D, Chowdary P, Sekhar M, Parikh P, Finkel J, et al. A stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia. Aliment Pharmacol Ther. 2019;50:1049–58.

    Article  CAS  PubMed  Google Scholar 

  32. Brunaud L, Antunes L, Collinet-Adler S, Marchal F, Ayav A, Bresler L, Boissel P. Acute mesenteric venous thrombosis: case for nonoperative management. J Vasc Surg. 2001;34:673–9.

    Article  CAS  PubMed  Google Scholar 

  33. Turnes J, Garcia-Pagan JC, Gonzalez M, Aracil C, Calleja JL, Ripoll C, Abraldes JG, et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol. 2008;6:1412–7.

    Article  PubMed  Google Scholar 

  34. Franceschet I, Zanetto A, Ferrarese A, Burra P, Senzolo M. Therapeutic approaches for portal biliopathy: a systematic review. World J Gastroenterol. 2016;22:9909–20.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Llop E, de Juan C, Seijo S, Garcia-Criado A, Abraldes JG, Bosch J, Garcia-Pagan JC. Portal cholangiopathy: radiological classification and natural history. Gut. 2011;60:853–60.

    Article  PubMed  Google Scholar 

  36. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology. 2000;32:466–70.

    Article  CAS  PubMed  Google Scholar 

  37. Amitrano L, Guardascione MA, Scaglione M, Pezzullo L, Sangiuliano N, Armellino MF, Manguso F, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;102:2464–70.

    Article  PubMed  Google Scholar 

  38. Janczak DT, Mimier MK, McBane RD, Kamath PS, Simmons BS, Bott-Kitslaar DM, Lenz CJ, et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc. 2018;93:40–7.

    Article  CAS  PubMed  Google Scholar 

  39. Nery F, Valadares D, Morais S, Gomes MT, De Gottardi A. Efficacy and safety of direct-acting oral anticoagulants use in acute portal vein thrombosis unrelated to cirrhosis. Gastroenterology Res. 2017;10:141–3.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, Schiano T, Mascarenhas J. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv. 2020;4:655–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. van Bijnen ST, van Rijn RS, Koljenovic S, te Boekhorst P, de Witte T, Muus P. Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab. Br J Haematol. 2012;157:762–3.

    Article  PubMed  Google Scholar 

  42. Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, Hadengue A, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490–7.

    Article  CAS  PubMed  Google Scholar 

  43. Spaander MC, Hoekstra J, Hansen BE, Van Buuren HR, Leebeek FW, Janssen HL. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11:452–9.

    Article  CAS  PubMed  Google Scholar 

  44. Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, Grandone E, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175:1474–80.

    Article  PubMed  Google Scholar 

  45. Riva N, Ageno W, Schulman S, Beyer-Westendorf J, Duce R, Malato A, Santoro R, et al. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematol. 2016;3:e267–75.

    Article  PubMed  Google Scholar 

  46. Orr DW, Harrison PM, Devlin J, Karani JB, Kane PA, Heaton ND, O’Grady JG, et al. Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clin Gastroenterol Hepatol. 2007;5:80–6.

    Article  CAS  PubMed  Google Scholar 

  47. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S–96S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Guillaume M, Christol C, Plessier A, Corbic M, Peron JM, Sommet A, Rautou PE, et al. Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation. Eur J Gastroenterol Hepatol. 2018;30:563–8.

    Article  PubMed  Google Scholar 

  49. Ponthus S, Spahr L, Casini A, Berney T, Frossard JL, Majno P, Elkrief L. Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: a retrospective study. Eur J Gastroenterol Hepatol. 2020;32:395–400.

    Article  PubMed  Google Scholar 

  50. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–9.

    Article  PubMed  Google Scholar 

  51. Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61:660–7.

    Article  CAS  PubMed  Google Scholar 

  52. Luca A, Caruso S, Milazzo M, Marrone G, Mamone G, Crino F, Maruzzelli L, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265:124–32.

    Article  PubMed  Google Scholar 

  53. Senzolo M, Sartori TM, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32:919–27.

    Article  CAS  PubMed  Google Scholar 

  54. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54:691–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Zanetto A, Garcia-Tsao G. Some answers and more questions about portal vein thrombosis in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol. 2020;18(11):2432–4.

    Article  PubMed  Google Scholar 

  56. Senzolo M, Riva N, Dentali F, Rodriguez-Castro K, Sartori MT, Bang SM, Martinelli I, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol. 2018;9:176.

    Article  PubMed  PubMed Central  Google Scholar 

  57. D’Amico G, De Franchis R, Cooperative SG. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599–612.

    Article  PubMed  Google Scholar 

  58. Zanetto A, Shalaby S, Feltracco P, Gambato M, Germani G, Russo FP, Burra P, et al. Recent advances in the management of acute variceal hemorrhage. J Clin Med. 2021;10(17):3818.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Zanetto A, Rodriguez-Kastro KI, Germani G, Ferrarese A, Cillo U, Burra P, Senzolo M. Mortality in liver transplant recipients with portal vein thrombosis—an updated meta-analysis. Transpl Int. 2018;31:1318–29.

    Article  PubMed  Google Scholar 

  60. Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013;58:1776–80.

    Article  CAS  PubMed  Google Scholar 

  61. Chung JW, Kim GH, Lee JH, Ok KS, Jang ES, Jeong SH, Kim JW. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol. 2014;20:384–91.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, et al. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2015;45:656–62.

    Article  CAS  PubMed  Google Scholar 

  63. Chen H, Liu L, Qi X, He C, Wu F, Fan D, Han G. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2016;28:82–9.

    Article  PubMed  Google Scholar 

  64. La Mura V, Braham S, Tosetti G, Branchi F, Bitto N, Moia M, Fracanzani AL, et al. Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2018;16:1146–52. e1144

    Article  PubMed  Google Scholar 

  65. Artaza T, Lopes M, Romero M, Gomez AZ, de la Cruz G, Sanchez JJ, Gonzalez C, et al. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis. Gastroenterol Hepatol. 2018;41:611–7.

    Article  PubMed  Google Scholar 

  66. Scheiner B, Stammet PR, Pokorny S, Bucsics T, Schwabl P, Brichta A, Thaler J, et al. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wien Klin Wochenschr. 2018;130:446–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Hayashi T, Takatori H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, et al. Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients. BMC Gastroenterol. 2019;19:217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Noronha Ferreira C, Reis D, Cortez-Pinto H, Tato Marinho R, Goncalves A, Palma S, Leite I, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis. Dig Dis Sci. 2019;64:2671–83.

    Article  CAS  PubMed  Google Scholar 

  69. Rodriguez-Castro KI, Vitale A, Fadin M, Shalaby S, Zerbinati P, Sartori MT, Landi S, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol. 2019;31:34–42.

    Article  PubMed  Google Scholar 

  70. Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, Sparchez Z, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114:258–66.

    Article  CAS  PubMed  Google Scholar 

  71. Senzolo M, Piano S, Shalaby S, Tonon M, Tonello S, Zanetto A, Sacerdoti D, et al. Comparison of fondaparinux and low-molecular-weight heparin in the treatment of portal vein thrombosis in cirrhosis. Am J Med. 2021;134:1278–85. e1272

    Article  CAS  PubMed  Google Scholar 

  72. Tripodi A, Primignani M, Braham S, Chantarangkul V, Clerici M, Moia M, Peyvandi F. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Dig Liver Dis. 2016;48:1208–13.

    Article  PubMed  Google Scholar 

  73. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44:448–51.

    Article  CAS  PubMed  Google Scholar 

  74. Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia-Criado A, Abraldes JG, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10:776–83.

    Article  PubMed  Google Scholar 

  75. Cui SB, Shu RH, Yan SP, Wu H, Chen Y, Wang L, Zhu Q. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol. 2015;27:914–9.

    Article  CAS  PubMed  Google Scholar 

  76. Russo FP, Zanetto A, Campello E, Bulato C, Shalaby S, Spiezia L, Gavasso S, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int. 2018;38:2210–8.

    Article  CAS  PubMed  Google Scholar 

  77. Kwon J, Koh Y, Yu SJ, Yoon JH. Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: efficacy and the risk of hemorrhagic complications. Thromb Res. 2018;163:71–6.

    Article  CAS  PubMed  Google Scholar 

  78. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73:366–413.

    Article  PubMed  Google Scholar 

  79. Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153:480–7. e481

    Article  CAS  PubMed  Google Scholar 

  80. Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, Spiezia L, et al. More pronounced hypercoagulable state and hypofibrinolysis in patients with cirrhosis with versus without HCC. Hepatol Commun. 2021;5(12):1987–2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Campello E, Zanetto A, Bulato C, Maggiolo S, Spiezia L, Russo FP, Gavasso S, et al. Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Liver Int. 2021;41:2455–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Zanetto A, Rinder HM, Senzolo M, Simioni P, Garcia-Tsao G. Reduced clot stability by thromboelastography as a potential indicator of procedure-related bleeding in decompensated cirrhosis. Hepatol Commun. 2021;5:272–82.

    Article  CAS  PubMed  Google Scholar 

  83. Zanetto A, Rinder HM, Campello E, Saggiorato G, Deng Y, Ciarleglio M, Wilson FP, et al. Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features. Hepatology. 2020;72:1327–40.

    Article  CAS  PubMed  Google Scholar 

  84. Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: report of a consensus conference. Dig Liver Dis. 2016;48:455–67.

    Article  Google Scholar 

  85. Lehman CM, Rettmann JA, Wilson LW, Markewitz BA. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol. 2006;126:416–21.

    Article  CAS  PubMed  Google Scholar 

  86. Brigden ML, Kay C, Le A, Graydon C, McLeod B. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol. 1998;59:22–7.

    Article  CAS  PubMed  Google Scholar 

  87. Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, et al. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia. J Am Coll Cardiol. 2017;70:2636–48.

    Article  CAS  PubMed  Google Scholar 

  88. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents—the selective factor Xa inhibitors. Cardiovasc Drug Rev. 2002;20:37–52.

    Article  CAS  PubMed  Google Scholar 

  89. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.

    Article  CAS  PubMed  Google Scholar 

  91. Sciarrone SS, Zanetto A, Russo FP, Germani G, Gambato M, Battistella S, Pellone M, et al. Malnourished cirrhotic patient: what should we do? Minerva Gastroenterol (Torino). 2021;67:11–22.

    Google Scholar 

  92. Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9:e017559.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One. 2014;9:e88390.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology. 2015;61:1435–6.

    Article  CAS  PubMed  Google Scholar 

  95. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61:1721–7.

    Article  CAS  PubMed  Google Scholar 

  96. Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98:393–7.

    Article  CAS  PubMed  Google Scholar 

  97. Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, Hatooka M, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48:51–8.

    Article  CAS  PubMed  Google Scholar 

  98. Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vasc Pharmacol. 2019;113:86–91.

    Article  CAS  Google Scholar 

  99. Semmler G, Pomej K, Bauer DJM, Balcar L, Simbrunner B, Binter T, Hartl L, et al. Safety of direct oral anticoagulants in patients with advanced liver disease. Liver Int. 2021;41:2159–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis. 2019;39:195–208.

    Article  CAS  PubMed  Google Scholar 

  101. Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hurlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61:293–300.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Padua, Italy

    Marco Senzolo & Alberto Zanetto

Authors
  1. Marco Senzolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Zanetto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Gastroenterology Unit, University of Milan, Milan, Milano, Italy

    Roberto de Franchis

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Senzolo, M., Zanetto, A. (2022). Anticoagulation in Splanchnic Vein Thrombosis With and Without Underlying Liver Disease. In: de Franchis, R. (eds) Portal Hypertension VII. Springer, Cham. https://doi.org/10.1007/978-3-031-08552-9_57

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-08552-9_57

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-08551-2

  • Online ISBN: 978-3-031-08552-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation